key: cord-0861156-9qhvm04f
authors: Janssen, Nico A F; Grondman, Inge; de Nooijer, Aline H; Boahen, Collins K; Koeken, Valerie A C M; Matzaraki, Vasiliki; Kumar, Vinod; He, Xuehui; Kox, Matthijs; Koenen, Hans J P M; Smeets, Ruben L; Joosten, Irma; Brüggemann, Roger J M; Kouijzer, Ilse J E; van der Hoeven, Hans G; Schouten, Jeroen A; Frenzel, Tim; Reijers, Monique; Hoefsloot, Wouter; Dofferhoff, Anton S M; van Apeldoorn, Marjan J; Blaauw, Marc J T; Veerman, Karin; Maas, Coen; Schoneveld, Arjan H; Hoefer, Imo E; Derde, Lennie P G; van Deuren, Marcel; van der Meer, Jos W M; van Crevel, Reinout; Giamarellos-Bourboulis, Evangelos J; Joosten, Leo A B; van den Heuvel, Michel M; Hoogerwerf, Jacobien; de Mast, Quirijn; Pickkers, Peter; Netea, Mihai G; van de Veerdonk, Frank L
title: Dysregulated innate and adaptive immune responses discriminate disease severity in COVID-19
date: 2021-02-01
journal: J Infect Dis
DOI: 10.1093/infdis/jiab065
sha: ba7220a19754b8ac1073479a1a52249a9b01cd43
doc_id: 861156
cord_uid: 9qhvm04f

The clinical spectrum of COVID-19 varies and the differences in host response characterizing this variation have not been fully elucidated. COVID-19 disease severity correlates with an excessive pro-inflammatory immune response and profound lymphopenia. Inflammatory responses according to disease severity were explored by plasma cytokine measurements and proteomics analysis in 147 COVID-19 patients. Furthermore, peripheral blood mononuclear cell cytokine production assays and whole blood flow cytometry were performed. Results confirm a hyperinflammatory innate immune state, while highlighting hepatocyte growth factor and stem cell factor as potential biomarkers for disease severity. Clustering analysis reveals no specific inflammatory endotypes in COVID-19 patients. Functional assays reveal abrogated adaptive cytokine production (interferon-gamma, interleukin-17 and interleukin-22) and prominent T cell exhaustion in critically ill patients, whereas innate immune responses were intact or hyperresponsive. Collectively, this extensive analysis provides a comprehensive insight into the pathobiology of severe to critical COVID-19 and highlight potential biomarkers of disease severity.

A c c e p t e d M a n u s c r i p t 6 

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has spread rapidly across the world and was officially declared a pandemic in March 2020 [1] . The clinical spectrum of coronavirus disease 2019 , caused by SARS-CoV-2, varies from asymptomatic disease or mild respiratory symptoms, to severe pneumonia, respiratory failure and death [2] .

So far, more than eighty million people have been infected, leading to more than 1,800,000 deaths worldwide [3] . Although much has been learned about the pathogenesis of COVID-19 in a very short time, the complex dysregulation of the immune system involved in progression of this disease still remains incompletely understood.

The most severe complication of COVID-19 is respiratory failure due to acute respiratory distress syndrome (ARDS), requiring ventilatory support in the intensive care unit (ICU).

Inflammation plays a central role in the pathogenesis of ARDS [4] . Evidence suggests that an exuberant innate immune response induced by SARS-CoV-2 characterizes more severe disease, as illustrated by higher concentrations of circulating pro-inflammatory cytokines in critically ill (ICU) COVID-19 patients as compared to non-ICU patients [2, [5] [6] [7] .

Furthermore, severely ill patients display a compromised adaptive immune system, characterized by T cell exhaustion and profound lymphopenia [5, [8] [9] [10] . These findings point towards dysregulation of both innate and adaptive immunity and the degree of perturbance might be associated with disease severity, potentially leading to the development of clinically useful biomarkers. Therefore, in this study, we integrated plasma cytokine measurements and proteomics to explore the inflammatory response in hospitalized patients with severe (non- 

All patients aged ≥ 18 years with polymerase chain reaction (PCR)-confirmed or clinically presumed COVID-19 admitted to medical wards and ICU in the Radboudumc between 05-03-2020 and 21-04-2020 were eligible for enrolment. Presumed infection was defined based on clinical signs and symptoms, specific CT findings and clinical expert consensus [11] . 

All applicable study protocols were approved by the local ethics board before initiation of the study. All patients admitted to hospital (or their representatives) either provided verbal informed consent for (non-ICU wards) or did not object to (ICU) participation before enrollment. This study was performed in accordance with the latest version of the 

Plasma was obtained from ethylenediaminetetraacetic acid (EDTA) blood by centrifugation and stored at either -20 C for later enzyme-linked immunosorbent assay (ELISA) or at -80 C for later proteomics analysis.

Clinical data were obtained from patients' medical files, and processed in encoded form in electronic case report forms (Castor electronic data capture, Amsterdam, the Netherlands). A c c e p t e d M a n u s c r i p t 9

Circulating plasma protein expression was assessed using the commercially available multiplex proximity extension assay from Olink Proteomics AB (Uppsala, Sweden) [12] .

Proteins from three different panels were measured (Inflammation, Cardiometabolic and Cardiovascular II), resulting in data on 269 different proteins in total.

To improve the chance of true positive discoveries, we validated the findings by assessing immune biomarkers in two cohorts: a discovery cohort for identification of proteins differentially expressed in ICU patients as compared to non-ICU patients, and a validation cohort to validate the findings from the discovery cohort.

Measurements were performed on two batches on separate occasions. The first batch included plasma samples donated between 18 and 25-03-2020, the second batch included plasma samples donated between 23-03-2020 and 23-04-2020. Because the second batch encompassed samples from a larger number of patients, patients whose samples were measured at this time were retrospectively assigned to the discovery cohort, whereas those whose samples were measured in the (smaller) first batch were retrospectively assigned to the validation cohort.

Proteins are expressed on a log2-scale as normalised protein expression (NPX) values, and were normalised using bridging samples to correct for batch variation. Louis, MO, USA) or heat-killed Candida albicans yeast cells (strain UC820) for 24 hours at 37 C and 5% CO 2 to assess TNF-α, IL-1β, IL-6 and IL-1Ra production. For 7 days' stimulation experiments (to assess IFN-, IL-17 and IL-22 production), wells were supplemented with 10% pooled human serum. After incubation, supernatants were collected and stored at -20 C before ELISA measurements were performed.

Whole blood cell counts were obtained using a Coulter Ac-T Diff cell counter (Beckman Coulter, Inc., Brea, CA, USA) which was calibrated daily. 1 ~ 1.5 mL of whole blood was 

For continuous variables, groups were compared using Mann-Whitney U test or Kruskal-Wallis test with Dunn's multiple comparison test, assuming non-Gaussian distribution of variables. Nominal variables were compared using the Chi-square or Fisher's exact test, as appropriate. A P-value < 0.05 was considered statistically significant. Receiver-operating characteristic (ROC) analyses for the performance of biomarkers in distinguishing disease severity were performed by designating values from non-ICU patients as control values and those from ICU patients as patient values. Differential expression (DE) analysis of Olink proteins between ICU and non-ICU groups was performed using the R package limma, applying a linear model with age and sex as covariates. Limma uses an empirical Bayes method to moderate the standard errors of the estimated log fold changes [13] . The Benjamini-Hochberg procedure was applied to correct for multiple testing, and an FDR < 0.05 was considered statistically significant. Statistical analyses were performed using A c c e p t e d M a n u s c r i p t 12 GraphPad Prism 5 or 8 for Windows (GraphPad Software, Inc., San Diego, CA, USA) or R/Bioconductor (https://www.R-project.org/).

147 Hospitalized COVID-19 patients donated plasma, 38 of whom were admitted to ICU and 109 to non-ICU clinical wards. Patient characteristics at hospital admission are provided in Table 1 . Demographic characteristics did not differ between the ICU and non-ICU groups at the time of hospitalization. However, in ICU patients, time to plasma sampling was significantly longer, co-morbid pulmonary and auto-immune diseases were significantly less frequent and C-reactive protein (CRP) levels and computed tomography (CT) severity scores at admission were significantly higher. Fig 1C) . Although TNF-α plasma levels were relatively low in both groups, they were also significantly higher in ICU patients (ICU: median 18.5 pg/mL versus non-ICU: 16 .0 pg/mL; Fig 1D) , although differences were small.

A c c e p t e d M a n u s c r i p t 13 

For proteomics analysis, the discovery cohort consisted of 101 (83 non-ICU and 18 ICU ) and the validation cohort of 46 patients (26 non-ICU and 20 ICU; Supplementary Fig 1) . Patient characteristics between the two cohorts were generally well matched (Supplementary Table   2 ). However, the discovery cohort contained relatively fewer ICU patients than the validation cohort (17.8% versus 43.5%, respectively, P = 0.002).

After quality control, normalisation of all assessed proteins for all samples and correction for age and sex as covariates, 40 proteins were found to be significantly higher in ICU patients versus non-ICU patients, whereas 24 were significantly lower (false discovery rate [FDR] < 0.05; Fig 2A) . In the validation cohort, this was the case for 19 and 30 proteins, respectively.

Overlap analysis and correcting P-values for multiple testing revealed 27 proteins overlapping between the two cohorts that were significantly differentially expressed in ICU versus non-ICU patients (Fig 2B) . Among these, hepatocyte growth factor (HGF; log2 fold revealed that the latter three demonstrated strong potential in discriminating disease severity, with AUC values similar to those for CRP and D-dimer and higher than that of ferritin ( Supplementary Fig 3) .

To identify any potential inflammatory endotypes in COVID-19, unsupervised hierarchical clustering analysis was performed on those proteins that were significantly differentially expressed between ICU and non-ICU patients in the discovery cohort. This revealed no significantly different protein signatures between patients: no specific inflammatory endotypes were identified (Fig 3) .

Immune cells' cytokine production and markers of activation and exhaustion were assessed in patients with COVID-19 and compared to healthy controls (HCs). In general, immune cells of COVID-19 patients did not demonstrate significant differences in the production capacity of TNF-α, IL-1β, IL-6 and IL-1 receptor antagonist (IL-1Ra) as compared to healthy controls upon stimulation with lipopolysaccharide (LPS) or C. albicans (Fig 4A-D) . However, ICU 

Our study provides several important findings. Our comprehensive approach demonstrates that critically ill COVID-19 patients are characterized by higher plasma concentrations of CRP, D-dimer, ferritin, IL-6 and TNF-α compared to less severely ill patients. In parallel, indepth analysis of differential protein expression highlights several potential biomarkers of disease severity. Of these, HGF and SCF can differentiate between critical and severe illness with approximately equal discriminatory performance as CRP, D-dimer and circulating IL-6, and better performance than ferritin. Next, clustering analysis of differential protein expression demonstrates that patients do not form clusters based on specific inflammatory endotypes. Furthermore, patients' innate immune cells show equal or even higher proinflammatory cytokine production after ex vivo stimulation, whereas adaptive cytokine production is significantly decreased in a seemingly severity dependent manner. Moreover, patients' CD4 + T cells display increased expression of PD-1, a marker of apoptosis and T cell exhaustion. On the other hand, HLA-DR expression on monocytes is significantly lower than in healthy controls. Collectively, all these findings point towards a general concept of a homogeneous inflammatory state in patients with COVID-19, combined with compromised T cell immune responses.

The observed relationship between the degree of elevation of pro-inflammatory markers and disease severity is in line with previous studies and has been recognized early in the COVID-19 pandemic [2, [5] [6] [7] . One may argue that differences in severity might be attributed to longer A c c e p t e d M a n u s c r i p t 17 disease duration, as time from hospital admission to blood sampling differed between these two groups (4 days in ICU versus 2 days in non-ICU patients). However, while this may have been a potential confounder theoretically, our population shows remarkable consistency in disease severity over time: only 3/109 non-ICU patients made a transition to the ICU during study follow-up, indicating a deterioration in disease severity. In-depth proteomics analysis revealed a multitude of potential markers of disease severity confirming that IL-6 is strongly upregulated in critically ill patients. Among these, prominently upregulated proteins include HGF and CCL20. Other studies have also shown increased HGF plasma concentrations in COVID-19 related to disease severity [15, 16] and have demonstrated upregulated expression of HGF induced by pro-inflammatory cytokines [17] and in viral infections such as hepatitis B [18] . CCL20 is a chemokine with a strong chemotactic effect on lymphocytes [19] and is also upregulated by pro-inflammatory cytokines. Therefore, its upregulation in critical COVID-19 might serve as a compensatory mechanism for lymphopenia, since multiple studies demonstrate a correlation between disease severity and degree of lymphopenia [2, 8] .

In contrast, CCL20 upregulation might cause lymphocyte abundance in the tissues [20] , leading to lymphocyte depletion in the peripheral blood.

In our proteomics analysis, SCF was most strongly downregulated. This ligand of the c-Kit receptor is a crucial factor in maintaining hematopoietic stem cells and lymphoid progenitor cells [21, 22] . Furthermore, a positive correlation between SCF and specific COVID-19 neutralizing antibody titers has recently been demonstrated [23]. One could speculate that reduced SCF expression might contribute to the observed lymphopenia in COVID-19 and lower antibody titers.

A c c e p t e d M a n u s c r i p t 18 Additional ex vivo functional analysis confirmed an enhanced innate cytokine response in COVID-19 patients (with the exception of the TNF-α response to C. albicans), and monocytic HLA-DR expression was only mildly decreased as opposed to the severe immune suppression seen in bacterial sepsis [14] . However, adaptive cytokine production was severely abrogated with apparent correlations with disease severity. This is in line with a recent study demonstrating impaired IFN-γ production in lymphocytes after stimulation with anti-CD3/anti-CD28 [24]. Adaptive immune system dysfunction was further supported by findings of increased expression of PD-1 on CD4 + T lymphocytes, consistent with previous data [10, 25] . In conclusion, our findings point towards a disease state characterized by a hyperinflammatory innate immune system and a defective adaptive immune system due to profound lymphopenia, exhausted T cells and decreased functionality. These findings are supported by a very recent study on the systems biology of severe versus mild COVID-19 patients, which has also shown a combination of increased systemic inflammation, low HLA-

Our study has several limitations. First, due to the explorative nature of our study, direct conclusions on causality between immunological profiles and disease severity cannot be inferred. However, we identified several potential biomarkers of severity, warranting further investigation, especially regarding their possible pathophysiological role in disease course and severity. Second, plasma sampling was not performed on predefined timepoints as a consequence of this study's pragmatic design. Differences in hospitalisation duration at the time of sampling might have influenced our results. Additionally, no correction for other potential confounders, such as comorbidity and medication use, was performed due to this approach. Third, we classified disease severity according to admission to ICU versus non-ICU wards, which might differ from classifications employed by other studies. Fourth, in the A c c e p t e d M a n u s c r i p t 19 proteomics analysis, patient assignment to the discovery or validation cohort was not completely random, but instead ultimately based on the date of plasma donation. Although introduction of bias due to this approach cannot be excluded, the fact that no significant changes in diagnostic work-up or therapeutic management of COVID-19 occurred between the sample collection periods of either cohort appears to minimise this risk. Last, in our ex vivo stimulation experiments, cellular composition of the PBMC fraction differed between the groups. Contamination with low-density granulocytes after Ficoll density centrifugation has been described before in sepsis [27] . To what degree cytokine production has been influenced by these differences is unclear. As the experiments were performed with PBMCs isolated from EDTA blood, and depletion of intracellular calcium has been suggested to impact cytokine production capacity, an impact on the overall strength of cytokine production capacity cannot be fully excluded, although potent cytokine release has been observed in this study.

In conclusion, our integrated and extensive approach demonstrates essential differences in innate and adaptive immune responses between severely and critically ill COVID-19 patients, presenting potential biomarkers of disease severity and elucidating its pathobiology. It further highlights a severely dysfunctional adaptive immune response, in the presence of a hyperinflammatory innate immune system. Further investigations of the crosstalk between innate and adaptive immunity in COVID-19 and their relationship with disease severity are highly warranted. 

World Health Organization

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

World Health Organization. COVID-19 Weekly Epidemiological Update

Accessed 08

Inflammasome-regulated cytokines are critical mediators of acute lung injury

Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients

Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors

Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19

Clinical Characteristics of Coronavirus Disease 2019 in China

Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China

Reduction and Functional Exhaustion of T Cells in Patients With Coronavirus Disease 2019 (COVID-19)

CO-RADS: A Categorical CT Assessment Scheme for Patients Suspected of Having COVID-19-Definition and Evaluation

Homogenous 96-plex PEA immunoassay exhibiting high sensitivity, specificity, and excellent scalability

limma powers differential expression analyses for RNA-sequencing and microarray studies

COVID-19 patients exhibit less pronounced immune suppression compared with bacterial septic shock patients

Plasma IP-10 and MCP-3 levels are highly associated with disease severity and predict the progression of COVID-19

Elevated plasma levels of selective cytokines in COVID-19 patients reflect viral load and lung injury

Up-regulation of hepatocyte growth factor gene expression by interleukin-1 in human skin fibroblasts

EGF and HGF levels are increased during active HBV infection and enhance survival signaling through extracellular matrix interactions in primary human hepatocytes

The CC chemokine CCL20 and its receptor CCR6

Pathological findings of COVID-19 associated with acute respiratory distress syndrome

Stem cell factor and hematopoiesis

Data are presented as median with interquartile range (IQR) or n (%)

BMI, body mass index. SCT, stem cell transplantation. SOT, solid organ transplantation. COPD, chronic obstructive pulmonary disease. CKD, chronic kidney disease. RRT, renal replacement therapy. HIV, human immunodeficiency virus. AIDS, acquired immunodeficiency syndrome. WBC, white blood cell count